KCM
PBYI icon

Kynam Capital Management’s Puma Biotechnology PBYI Stock Holding History

Kynam Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-473,975
Closed -$1.25M – 31
2023
Q3 		$1.25M Buy
473,975
+905
+0.2% +$3.08K 0.2% 25
2023
Q2 		$1.67M Hold
473,070
– – 0.23% 20
2023
Q1 		$1.46M Sell
473,070
-88,539
-16% -$334K 0.19% 29
2022
Q4 		$2.38M Buy
561,609
+1,840
+0.3% +$6.35K 0.36% 25
2022
Q3 		$1.33M Sell
559,769
-20,146
-3% -$58.8K 0.28% 28
2022
Q2 		$1.65M Sell
579,915
-73,530
-11% -$183K 0.42% 26
2022
Q1 		$1.88M Sell
653,445
-30,174
-4% -$78K 0.61% 22
2021
Q4 		$2.08M Buy
+683,619
New +$2.97M 1.11% 24

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Kynam Capital Management's PBYI Position: Q4 2023 in Review

Kynam Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2023, closing a stake of 473,975 shares — an estimated $1.25M sold.

Kynam Capital Management first reported a position in PBYI in Q4 2021 and held it in 8 quarters. The position peaked at $2.38M in Q4 2022. 82 funds tracked by Wall St. Rank hold PBYI as of Q4 2023.

  • Kynam Capital Management reported no remaining Puma Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Kynam Capital Management sold 473,975 Puma Biotechnology shares in Q4 2023, an estimated $1.25M.
  • Kynam Capital Management first reported a position in Puma Biotechnology in Q4 2021 and held it in 8 quarters.
  • Kynam Capital Management's Puma Biotechnology position peaked at $2.38M in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2023.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.